Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715039 · ClinicalTrials.gov registry record · NA
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 169
- Enrollment target
NCT00715039 is a NA study that has completed, run by Pfizer. The registered enrollment target is 169 participants.
The verdict
NCT00715039, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 169 participants
- Enrollment target
Study Summary
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
Interventions
- DRUG placebo
- DRUG paroxetine
- DRUG lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00715039
The ClinicalTrials.gov registry entry for NCT00715039 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00715039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00715039 about?
NCT00715039 is a clinical study titled "Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder". The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
What is the current status of trial NCT00715039?
This trial is currently completed. It is a NA study. The enrollment target is 169 participants. The study started on 2003-10. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00715039?
The interventions under investigation include: placebo (DRUG), paroxetine (DRUG), lorazepam (DRUG).
Who is sponsoring clinical trial NCT00715039?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.